Gilead's remdesivir slows disease progression in monkeys with Covid-19

Remdesivir did not show signs of respiratory disease and had reduced damage to the lungs

US pharma giant Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaques infected with the new coronavirus, according to a study published in medical journal Nature on Tuesday, Reuters reported.

Remdesivir has been cleared for emergency use in severely-ill patients in the United States, India and South Korea. Some European nations are also using it under compassionate programs.

Trials of the drug in humans are ongoing, and early data has shown the drug helped patients recover more quickly from the illness caused